Avita Medical, Inc.
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Cary Guy Vance
- Full Time Employees
- 226
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- 28159 Avenue Stanford Valencia CA United States 91355
- IPO Date
- Mar 18, 2012
- CIK
- 0001762303
- Website
- avitamedical.com
- Similar Companies
- Business
- AVITA Medical, Inc. (NASDAQ: RCEL; ASX: AVH) is a commercial-stage regenerative medicine company focused on therapeutic acute wound care solutions that accelerate skin healing and patient recovery. Founded in 1993 as Clinical Cell Culture in Perth, Western Australia, and restructured as AVITA Medical in 2008 with current headquarters in Valencia, California, the company develops and commercializes autologous cell-based technologies including its lead product, the RECELL System, an FDA-approved device for treating thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions; PermeaDerm, a biosynthetic wound matrix; and Cohealyx, a branded collagen-based dermal matrix, all marketed primarily in the United States with distribution and operations extending to Japan, the European Union, Australia, the United Kingdom, and New Zealand. The RECELL System utilizes a patient's own skin sample processed at point-of-care to produce Spray-On Skin Cells via single-use RECELL GO cartridges and multi-use processing devices, enabling reduced donor site requirements and improved outcomes for burns, trauma, surgical wounds, and vitiligo in hospitals, burn centers, dermatology clinics, and plastic surgery settings. Recent developments include an exclusive multi-year development and distribution agreement with Regenity Biosciences announced in July 2024 for a novel collagen-based dermal matrix (branded Cohealyx), anticipated to receive FDA 510(k) clearance in late 2024 for U.S. commercialization alongside potential expansion to the EU, Australia, and Japan; an exclusive distribution partnership with Revolution Surgical Pty Ltd in November 2024 to reintroduce RECELL into Australia and New Zealand; FDA approval expansions for RECELL in vitiligo and soft tissue reconstruction boosting 2025 commercial revenues to $18.4 million in Q2 (up 21% year-over-year); and a name change from AVITA Therapeutics, Inc. to AVITA Medical, Inc. to better reflect its wound care focus.
Company News
AVITA Medical to Announce Third Quarter 2026 Financial Results
Head-To-Head Comparison: Organigram Global (NASDAQ:OGI) versus Avita Medical (NASDAQ:RCEL)
Leading Indicators For The October Breakout Cycle
Is AVITA Medical Inc (RCEL) Overvalued After 5.9% Rally? GF Value Says Overvalued
NewEdge Advisors LLC Purchases 62,046 Shares of Avita Medical Inc. $RCEL
AVITA Medical, Inc. (RCEL) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
AVITA Medical to Participate in Lake Street Best Ideas Growth Conference and Morgan Stanley Healthcare Conference
All You Need to Know About Avita Medical (RCEL) Rating Upgrade to Buy
Avita Medical Inc. (RCEL) is a Great Momentum Stock: Should You Buy?
AVITA Medical: Favorable Reimbursements For Skin Wound Care
Avita Medical PermeaDerm Study Shows 70% Cost Reduction vs. Allograft
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical Announces Positive PermeaDerm® Study Results Demonstrating 70% Economic Advantage over Allograft and Comparable Clinical Outcomes
Avita Medical Raises 2026 Revenue Outlook as Q2 Sales Climb 18%
Avita Medical Targets Q4 2025 Cash Flow Breakeven as Revenue Growth Builds
AVITA Medical, Inc. (RCEL) Shareholder/Analyst Call Transcript
AVITA Medical to Host Investor Webinar Briefing
AVITA Medical Announces Participation at Canaccord Genuity Growth Conference
Avita Medical Q2 Earnings Call Highlights
AVITA Medical, Inc. (RCEL) Q2 2026 Earnings Call Transcript